Lipid comprising polyunsaturated fatty acids

Patent metadata

Field	Value
Publication number	US-9550718-B2
Application number	US-201414464510-A
Country	US
Kind code	B2
Filing date	Aug 20, 2014
Priority date	Jun 15, 2012
Publication date	Jan 24, 2017
Grant date	Jan 24, 2017

Abstract

The present invention relates to extracted plant lipid, comprising fatty acids in an esterified form.

First claim

The invention claimed is:

1. Extracted lipid from Brassica or Aradidopsis seeds, whose total fatty acid content comprises
(a) a total monounsaturated fatty acid content which comprises oleic acid,
(b) a total saturated fatty acid content which comprises palmitic acid and, if present, myristic acid (C14:0),
(c) a total ω6 fatty acid content which comprises linoleic acid (LA),
(d) a ω3 fatty acid content,
(e) less than 1% myristic acid (C14:0), and
(f) less than 4% eicosatrienoic acid (ETrA),
wherein
(i) a level of DHA between 7% and 20% is present in the total fatty acid content of the extracted lipid, wherein at least 70% of the DHA is esterified at the sn-1 or sn-3 position of triacylglycerol (TAG),
(ii) a level of palmitic acid between 2% and 16% is present in the total fatty acid content of the extracted lipid,
(iii) a level of linoleic acid (LA) between 4% and 35% is present in the total fatty acid content of the extracted lipid,
(iv) the total saturated fatty acid content of the extracted lipid is between 4% and 25% of the total fatty acid content,
(v) the ratio of the total ω6 fatty acid content to the ω3 fatty acid content in total of the extracted lipid is between 0.1 and 3.0, and
(vi) at least 70% of the total fatty acid content of the extracted lipid is esterified in the form of TAG.

2. The extracted lipid of claim 1 which has one or more or all of the following features
i) a level of palmitic acid between 2% and 15% is present in the total fatty acid content of the extracted lipid,
ii) a level of eicosatrienoic acid (ETrA) between 0.05% and about 2% is present in the total fatty acid content of the extracted lipid,
iii) the extracted lipid has a level of SPA of less than about 0.1%, EPA of less than about 0.1%, and ETA of less than about 0.1% in its total fatty acid content,
iv) the total monounsaturated fatty acid content in the extracted lipid is between about 4% and about 35% of the total fatty acid content,
v) the extracted lipid comprises new ω6 fatty acids in the total ω6 fatty acid content, wherein the level of new ω6 fatty acids in the extracted lipid is less than about 10% of the total fatty acid content,
vi) the ω3 fatty acid content in total in the extracted lipid is between 36% and about 65% of the total fatty acid content,
vii) the ratio of the total ω6 fatty acid content to the ω3 fatty acid content in total in the extracted lipid is between about 0.1 and about 0.5,
viii) the extracted lipid comprises new ω3 fatty acids in the ω3 fatty acid content in total and new ω6 fatty acids in the total ω6 fatty acid content, wherein the ratio of the new ω6 fatty acids to the new ω3 fatty acids in the fatty acid content of the extracted lipid is between about 0.1 and about 1,
ix) the extracted lipid has a fatty acid composition based on an efficiency of conversion of oleic acid to DHA of at least about 10%,
x) the extracted lipid has a fatty acid composition based on an efficiency of conversion of LA to DHA of at least about 15%,
xi) the extracted lipid has a fatty acid composition based on an efficiency of conversion of ALA to DHA of at least about 17%,
xii) the total fatty acid content in the extracted lipid has less than 1% C20:1,
xiii) at least about 80% of the total fatty acid content of the extracted lipid is esterified in the form of TAG,
xiv) the extracted lipid comprises diacylglycerol (DAG), and
xv) the extracted lipid comprises less than about 10% free (non-esterified) fatty acids and/or phospholipid.

3. The extracted lipid of claim 1 which is in the form of an oil, wherein the oil comprises one or more sterols.

4. The extracted lipid of claim 3 , wherein the oil comprises less than 10 mg of sterols/g of oil.

5. The extracted lipid of claim 3 , wherein the oil comprises one or more or all of campesterol, Δ5-stigmasterol, eburicol, β-sitosterol, Δ5-avenasterol, Δ7-stigmasterol and Δ7-avenasterol.

6. The extracted lipid of claim 1 , which is from canola seed.

7. The extracted lipid of claim 1 , wherein a level of linoleic acid between 4% and about 20% is present in the total fatty acid content of the extracted lipid.

8. The extracted lipid of claim 1 , wherein a level of α-linolenic acid (ALA) between about 10% and about 35% is present in the total fatty acid content of the extracted lipid.

9. The extracted lipid of claim 1 , wherein a level of α-linolenic acid (ALA) between about 2% and about 16% is present in the total fatty acid content of the extracted lipid.

10. The extracted lipid of claim 1 , wherein a level of γ-linolenic acid (GLA) less than 4% is present in the total fatty acid content of the extracted lipid.

11. The extracted lipid of claim 1 , wherein a level of stearidonic acid (SDA) between 0.05% and about 7% is present in the total fatty acid content of the extracted lipid.

12. The extracted lipid of claim 1 , wherein a level of eicosatetraenoic acid (ETA) between 0.05% and about 4% is present in the total fatty acid content of the extracted lipid.

13. The extracted lipid of claim 1 , wherein a level of eicosapentaenoic acid (EPA) less than 4% is present in the total fatty acid content of the extracted lipid.

14. The extracted lipid of claim 1 , wherein a level of docosapentaenoic acid (DPA) between 0.05% and 8% is present in the total fatty acid content of the extracted lipid.

15. The extracted lipid of claim 1 , wherein a level of DHA between about 10% and 20% is present in the total fatty acid content of the extracted lipid.

16. The extracted lipid of claim 1 , wherein a level of DHA between about 11% and 20% is present in the total fatty acid content of the extracted lipid.

17. The extracted lipid of claim 1 , wherein the extracted lipid comprises less than about 0.1% ω6-docosapentaenoic acid (22:5 Δ4, 7, 10, 13, 16 ) in its total fatty acid content.

18. The extracted lipid of claim 1 , wherein the total saturated fatty acid content in the extracted lipid is between about 4% and about 20% of the total fatty acid content.

19. The extracted lipid of claim 1 , wherein the total monounsaturated fatty acid content in the extracted lipid is between about 4% and about 35% of the total fatty acid content.

20. The extracted lipid of claim 1 , wherein the extracted lipid comprises a total polyunsaturated fatty acid content comprising the total ω6 fatty acid content and the ω3 fatty acid content in total, wherein the total polyunsaturated fatty acid content in the extracted lipid is between about 20 and about 75% of the total fatty acid content.

21. The extracted lipid of claim 1 , wherein the extracted plant lipid comprises new ω3 fatty acids in the ω3 fatty acid content in total, wherein the level of new ω3 fatty acids in the extracted lipid is between 9% and about 33% of the total fatty acid content.

22. The extracted lipid of claim 1 , wherein at least 80% of the DHA esterified in the form of TAG is in the sn-1 or sn-3 position of the TAG.

23. The extracted lipid of claim 1 , wherein the most abundant DHA-containing TAG species in the lipid is DNA/18:3/18:3 (TAG 58:12).

24. The extracted lipid of claim 1 , wherein the extracted lipid comprises tri-DHA TAG (TAG 66:18).

25. The extracted lipid of claim 1 , which comprises ω6-docosapentaenoic acid (22:5 Δ4, 7, 10, 13, 16 ) in its total fatty acid content.

26. The extracted lipid of claim 1 , wherein the total ω6 fatty acid content in the extracted lipid is less than 20% of th

Assignees

• Commw Scient Ind Res Org
• Grains Res & Dev Corp
• Nuseed Pty Ltd

Inventors

• Petrie James Robertson
• Singh Surinder Pal
• De Feyter Robert Charles

Classifications

• A61P31/18

  for HIV · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/06

  Antiarrhythmics · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title